Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Under terms of the CRADA, Tessa will collaborate with the NCI’s DCTD to identify potential opportunities to expand the applicability of TT11X, Tessa’s allogeneic off-the-shelf CD30.CAR-modified EBVST cell therapy, as a treatment of non-Hodgkin lympho...
Product Name : TT11X
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 03, 2023
Lead Product(s) : TT11X,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.
Product Name : TT11X
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 16, 2023
Lead Product(s) : TT11X,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). The CD30.CAR-T cell therapy was demonstrated to be well tolerated with no unexpected safety signals...
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Polaris Partners
Deal Size : $126.0 million
Deal Type : Series A Financing
Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
Details : Tessa plans to use the proceeds from the financing to advance the ongoing clinical development of the company’s autologous CD30-CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X) programs.
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Polaris Partners
Deal Size : $126.0 million
Deal Type : Series A Financing
Lead Product(s) : TT11,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 17, 2022
Lead Product(s) : TT11,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT11X (CD30.CAR-EBVST cells) utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas.
Product Name : TT11X
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT11 – is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma.
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 13, 2022
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TT11X
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
Product Name : TT11X
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : TT11X
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Details : The PRIME designation was granted to TT11 by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center.
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 18, 2021
Lead Product(s) : TT11,Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tessa gets RMAT designation for new CAR-T
Details : The designation is based on the data of two independent Phase I/II trials, which show promising efficacy and strong safety profile of the therapy in Hodgkin lymphoma patients.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 27, 2020
Reset All
